Serum and cerebrospinal fluid urate levels in synucleinopathies versus tauopathies
Article first published online: 23 SEP 2012
© 2012 John Wiley & Sons A/S
Acta Neurologica Scandinavica
Volume 127, Issue 2, pages e8–e12, February 2013
How to Cite
Serum and cerebrospinal fluid urate levels in synucleinopathies versus tauopathies. Acta Neurol Scand 2013; 127: e8–e12. © 2012 John Wiley & Sons A/S., , , .
- Issue published online: 22 JAN 2013
- Article first published online: 23 SEP 2012
- Manuscript Accepted: 21 AUG 2012
- Parkinson's disease;
- atypical parkinsonian disorders;
- cerebrospinal fluid
Low levels of serum urate are associated with a higher risk of Parkinson's disease (PD). Higher serum and cerebrospinal fluid (CSF) urate levels are associated with slower rates of clinical decline in PD and in multiple system atrophy (MSA).
To compare CSF and blood urate levels in healthy controls, patients with synucleinopathies and with tauopathies.
We investigated urate levels in serum and CSF from 18 healthy controls, 19 patients with synucleinopathies (six patients with PD and 13 with MSA), and 24 patients with tauopathies (18 with progressive supranuclear palsy and six with corticobasal degeneration). None of the patients were treated with dopaminergic medications.
No significant differences were seen when comparing serum and CSF urate levels from controls across the parkinsonian diagnostic groups. However, in men, serum urate levels were significantly lower in the synucleinopathy group compared with the tauopathy group (P = 0.046), although with a broad overlap.
Our study suggests that urate levels might provide new insights into the potential pathophysiological mechanisms underlying Parkinsonism and thereby contribute to the future management of these disorders.